Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.
An elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which causes progressive optic neuropathy. Lowering IOP is currently the only therapeutic approach to the treatment of glaucoma. Tafluprost, a novel prostaglandin analogue, was recently launched onto the market as an ocular hypotensive agent. Tafluprost is potent in its affinity for the prostanoid FP receptor and in its intraocular lowering efficacy. Moreover, it enhances the ocular hemodynamics and has neuroprotective effects. Clinical studies have demonstrated its efficacy at decreasing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Aihara
Makoto
M
Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan. aihara-tky@umin.net
J Ocul Pharmacol Ther. 2008 Oct;24(5):521-6
18808364
Acta Ophthalmol Suppl (Oxf ). 2008;242:14-9
18752510
Br J Pharmacol. 2008 Jul;154(5):1079-93
18587449
Ophthalmology. 2004 Sep;111(9):1641-8
15350316
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63
16249494
Exp Eye Res. 2004 Apr;78(4):767-76
15037111
Exp Eye Res. 2008 Sep;87(3):251-6
18602392
Surv Ophthalmol. 2001 May;45 Suppl 4:S337-45
11434936
Acta Ophthalmol Suppl (Oxf ). 2008;242:7-13
18752509
J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15
14733708
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1353-60
19551401
Ophthalmology. 2005 Oct;112(10):1661-9
16111758
J Ocul Pharmacol Ther. 2007 Aug;23(4):359-65
17803434
Drug Metab Dispos. 2009 Aug;37(8):1622-34
19477946
Int J Clin Pharmacol Ther. 2008 Aug;46(8):400-6
18793581
Br J Ophthalmol. 2007 May;91(5):673-6
17124244
Eur J Ophthalmol. 2009 Mar-Apr;19(2):214-22
19253237